What Happens When You Stop Taking GLP-1 Weight Loss Medication?

GLP-1 medications such as semaglutide (Wegovy®) and tirzepatide (Mounjaro®) have transformed obesity treatment, helping many people achieve significant and sustained weight loss for the first time. But one question comes up in almost every time I discuss this topic:

“What happens when I stop taking it?”

The short answer is that it depends—but for many people, weight regain is common. That doesn’t mean the medication has “failed”, nor does it mean you’ve done anything wrong. It reflects the biology of obesity, which is increasingly recognised as a chronic, relapsing condition rather than simply a matter of willpower.

Why does weight come back?

GLP-1 medications work by reducing appetite, increasing feelings of fullness, slowing stomach emptying and improving blood sugar regulation.

While you’re taking them, many people find that:

• Food noise becomes quieter.

• Portion sizes naturally decrease.

• Cravings become easier to manage.

• Weight loss feels more sustainable.

When the medication is stopped, those biological effects MAY gradually fade. Your body’s appetite-regulating hormones begin returning towards their previous levels, hunger increases, and the body often tries to restore the weight it has lost. This is sometimes referred to as metabolic adaptation, a protective mechanism designed to prevent weight loss rather than maintain it (1).  However, this is not always the case. Sometimes our physiology can adapt and the same feels that used to drive our body to eat more are reduced after GLP-1 medication. 

What does the research show?

Clinical trials have consistently found that many people regain a substantial proportion of their lost weight after stopping GLP-1 therapy.

One of the best-known studies, the STEP 1 extension trial, found that participants regained around two-thirds of the weight they had lost during the year after stopping semaglutide. Many of the improvements in blood pressure, cholesterol and blood sugar also began to reverse (2). More recent evidence looking across multiple studies reached a similar conclusion: weight, waist circumference, blood glucose and other metabolic markers tend to worsen after treatment ends, although the degree of regain varies considerably between individuals (1). Importantly, not everyone returns to their starting weight, and some people maintain a significant proportion of their weight loss.

Why do some people maintain weight loss after stopping GLP-1 therapy?

Although weight regain is common after discontinuing GLP-1 receptor agonists, it is not universal. Researchers increasingly recognise that the body's response to weight loss is highly individual. In some people, prolonged weight reduction may be accompanied by partial "resetting" of physiological systems involved in appetite regulation, energy balance, and metabolic health. Improvements in insulin sensitivity, reductions in chronic inflammation, changes in food preferences and eating behaviours, and sustained lifestyle modifications adopted during treatment may help support long-term weight maintenance. There is also evidence that maintaining a lower weight for an extended period can attenuate some of the compensatory biological responses that normally drive weight regain, such as increased hunger and reduced energy expenditure. However, the extent to which these adaptations occur varies considerably between individuals and remains an active area of research. Consequently, while many people regain a significant proportion of lost weight after stopping GLP-1 therapy, others are able to maintain some or even most of their weight loss, suggesting that the physiological "set point" regulating body weight may be more flexible than previously thought (1,2). Although this point must be read with cautious (scientifically speaking) because there is currently limited evidence that GLP-1s permanently "reset" body-weight set points, but there is growing evidence that long-term weight loss can lead to durable changes in appetite regulation and metabolism in at least some individuals.

Why isn’t this simply about willpower?

Yet in those people that do put the weight back on, there is a great deal of quilt. Many people blame themselves if they regain weight.

In reality, obesity is influenced by powerful biological systems that regulate body weight.

After weight loss, the body responds with a number of changes (listed below). These changes can persist for years.

• Increasing hunger hormones

• Reducing feelings of fullness

• Making food more rewarding

• Lowering energy expenditure

GLP-1 medications help counteract these biological signals while they are being taken. Once treatment stops, those underlying drivers often return. This is why many obesity specialists now compare GLP-1 treatment to medication for high blood pressure or asthma—when treatment stops, the underlying condition often returns (3). 

Does everyone need to stay on GLP-1 medication forever?

Not necessarily. Some people can successfully stop treatment while maintaining most of their weight loss, particularly if they have built sustainable lifestyle habits alongside medication.

Factors that may improve long-term success include:

• Preserving muscle mass through resistance training

• Eating sufficient protein

• Regular physical activity

• Good sleep

• Ongoing behavioural support

• Early intervention if weight begins to increase

• 
  

However, for many people with longstanding obesity, long-term medication may be the most effective way to maintain both weight loss and improvements in metabolic health. Current evidence increasingly supports obesity as a chronic disease that often requires ongoing management.

Is there a better way to come off the medication?

Stopping suddenly isn’t always the best approach.

Some clinicians now recommend gradually reducing the dose while strengthening nutrition, exercise and behavioural strategies. Although research into tapering is still developing, many experts believe it may help soften the return of appetite for some individuals. 

Every decision should be made with your prescribing clinician, taking into account:

• Your weight history

• Medical conditions

• Side effects

• Pregnancy plans

• Cost and access to treatment

• Personal goals

Focus on health—not just the number on the scales

One of the biggest misconceptions is that GLP-1 medications are a “quick fix.” In reality, they are one tool within a broader strategy for improving metabolic health. Successful long-term management involves combining medication—where appropriate—with nutrition, movement, sleep, stress management and ongoing support. Whether someone remains on treatment, tapers off, or eventually stops altogether, the goal is not simply losing weight—it’s improving long-term health and quality of life.

T

he Bottom Line

Stopping GLP-1 medication doesn’t mean your journey is over—but it does require a plan.

Weight regain is common because the biological drivers of obesity often return when treatment ends. This isn’t a failure of motivation; it’s how the body is designed to protect against weight loss.

With the right support, many people can preserve much of their progress, whether through long-term medication, structured lifestyle changes, or a combination of both.

At Metabolic Health, we believe obesity should be managed like any other chronic health condition—with evidence-based treatment, ongoing support and a personalised approach that works for the individual.

1. Tzang CC, Wu PH, Luo CA, Chen ZT, Lee YT, Huang ES, Kang YF, Lin WC, Tzang BS, Hsu TC. Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. EClinicalMedicine. 2025 Nov 28;90:103680. doi: 10.1016/j.eclinm.2025.103680. PMID: 41399474; PMCID: PMC12702299.

2. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725

3. Horn DB, Linetzky B, Davies MJ, et al. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial. JAMA Intern Med. 2026;186(2):157–167. doi:10.1001/jamainternmed.2025.6112

   
   

#GLP-1, #weightloss #fatloss #Wegovy #Mounjaro